This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Cixutumumab

Eli Lilly & Company

Drug Names(s): ImClone/IMC-A12, LY3012217

Description: ImClone-A12 is a human monoclonal antibody directed at the insulin-like growth factor receptor. In preclinical models, IMC-A12 inhibited ligand-dependent signaling in human breast, colon and pancreatic tumor cell lines, which resulted in a reduction of cancer cell proliferation and survival.

Deal Structure: IMC-A12 was selected from a Dyax Phage Display library. In 1997, Dyax licensed its Ladner Phage Display patents to CAT and CAT granted certain limited rights to Dyax in relation to its Phage Display technology patents. In 2003, CAT and Dyax agreed to expand this access and to grant freedom to operate under each other's Phage Display technology patents. CAT granted Dyax worldwide licences for research purposes accessing all the Phage Display technology patents controlled by CAT and options for licences to develop therapeutic and diagnostic antibody products under CAT's patents. In return CAT will receive milestone and royalty payments on antibody products successfully developed by Dyax and its licensees.

CAT was acquired by AstraZeneca in 2006.

In November 2008 Eli Lilly completed the acquisition of ImClone Systems.

Partners: AstraZeneca PLC Shire Pharmaceuticals Group PLC


Cixutumumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug